Phase 1b/2, Multicenter, Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose and Recommended Phase 2 Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Hepatocellular Carcinoma (HCC)
Phase of Trial: Phase I/II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs DCR MYC (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Dicerna Pharmaceuticals
- 03 Aug 2017 Status changed from active, no longer recruiting to discontinued as per the sponsor decision.
- 25 Jul 2017 Planned End Date changed from 1 Dec 2016 to 31 Jul 2017.
- 25 Jul 2017 Planned primary completion date changed from 1 Oct 2016 to 31 Jul 2017.